Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4025-4037

  Yunos, Nurhanan M ^a,b   Beale, Philip ^c   Yu, Jun Q ^a   Strain, Dana ^a   Huq, Fazlul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FOREST RESEARCH INSTITUTE MALAYSIA   (Malaysia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Cisplatin; Colchicine; Drug combination; Ovarian cancer; Oxaliplatin; Paclitaxel; Synergism; Transplatinum

Indexed keywords

[TRANS PTCL2(AMMINO){IMIDAZO (1,2 ALPHA)PYRIDINE}]; [{TRANS PTCL(NH3)2}2{TRANS PT(3 HYDROXYPYRIDINE)2(H2N(CH2) 6NH2)2}CL4]; ANTINEOPLASTIC AGENT; CISPLATIN; COLCHICINE; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLCHICINE; DNA ADDUCTS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 78650232201     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Gallion HH, Pieretti M, DePriest PD and van Nagell J: The molecular basis of ovarian cancer. Cancer 76: 1992-1997, 1995.
3. Schuijer M and Berns EMJJ: TP53 and ovarian cancer. Human Mutat 21: 285-291, 2003.
4. Pinedo HM and Schornagel JH (eds.): Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. New York: Plenum Press, 1996.
5. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu J-J, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz J-E and M. Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95-98, 1996. (Pubitemid 26051870)
6. Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H, Caillet H and Cvitkovic E: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7: 1065-1070, 1996. (Pubitemid 27050831)
7. Di Francesco AM, Ruggiero A and Riccardi R: Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell MoI Life Sci 59: 1914-1927, 2002.
8. Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E, Quasthoff S, Grosskreutz J and Adelsberger H: Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Canc 2: 54-58, 2002. (Pubitemid 34704965)
9. Farrell N, Kelland LR, Roberts JD and Van Beusichem M: Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res 52: 5065-5072, 1992.
10. 2, where L=2-hydroxypyridine, imidazole, 3-hydroxypyridine and imidazo(1,2-α)pyridine. J Inorganic Biochem 98: 1261-1270, 2004.
11. 2 where L=2-hydroxypyridine, 3-hydroxypyridine, imidazole, and imidazo(1,2-α)pyridine. Eur J Med Chem 39: 691-697, 2004.
12. 4 in ovarian cancer cell lines. Chem Med Chem 3: 145-151, 2008.
13. Piccart MJ, Lamb H and Vermorken JB: Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 12: 1195-1203, 2001. (Pubitemid 32994741)
14. Wall ME and Wani MC: Camtothecin and taxol: Discovery to clinic-Thirteenth Bruce F. Cain Memorial Award lecture. Cancer Res 55: 753-760, 1995.
15. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979. (Pubitemid 9114288)
16. Shah MA and Schwartz GK: The relevance of drug sequence in combination chemotherapy. Drug Resist Updat 3: 335-336, 2000.
17. Rowinsky EK: Incorporating assessments of sequence-dependence in developmental studies of combination chemotherapy regimens containing new agents and platinum compounds. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Pinedo HM and Schornagel JH (eds.). New York, Plenum Press, 1996.
18. Agarwal PR and Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516, 2003.
19. Daud A, Munster P and Spriggs DR: New drugs in gynecologic cancer. Curr Treat Options in Oncol 2: 119-128, 2001.
20. 2]. Indian J Chem 8: 193-194, 1970.
21. Freshney RI: Culture of Animal Cells: A Manual of Basic Technique. New York, Wiley-Liss, 1994.
22. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
23. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
24. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies (erratum appears in Pharmacol Rev 59: 124, 2007). Pharmacol Rev 58(3): 621-681, 2006.
25. Bowtell DD: Rapid isolation of eukaryotic DNA. Anal Biochem 162: 463-465, 1987.
26. Solomon LA, Ali S, Banerjee S, Munkarah AF, Morris RT and Sarkar FH. Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB. J Ovarian Res 1: 9, 2008.
27. Perussi JR, Paltoo DN and Toppin VAL: Synergism between dipridamole and cisplatin in human breast cancer cells in vitro. Quim Nova 26: 3340-3343, 2008.
28. Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu P-H, Del va R, Lotz J-P, Belle SV, Extra J-M and Cvitkovic E: A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 17: 429-436, 2006.
29. Rogers P, Boxall FE, Allott CP, Stephens TC and Kelland LR: Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Eur J Cancer 38: 1653-1660, 2002. (Pubitemid 34876506)
30. Jandial DD, Farshi-Heydari S, Larson CA, Elliot GI, Wrasidlo WJ and Howell SB: Enhanced delivery of cisplatin to itraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15(2): 553-560, 2009.